Singota Solutions Opens New European Facility

Bloomington, IN - Bloomington-based Singota Solutions is expanding its international footprint with the opening of its second pharmaceutical storage facility in Switzerland.

The contract development and manufacturing organization says the 100,000-square-foot facility in Balerna was built in response to growing demand from its European pharmaceutical clients.

“This specific facility…allows our pharmaceutical clients to store their raw materials and their finished goods, so they can deploy those things globally at the drop of a hat as needed in response to market conditions,” said Anna Benefiel, senior director of business development and marketing for Singota.

Singota plans to add nearly 50 jobs at the Balerna site by the end of 2025, and a spokesperson said the facility can ultimately employ about 80 people, including warehouse, office and driver positions.

The company is not disclosing its financial investment in the project.

The new facility features 4,000 pallet positions that can store products in temperatures ranging from 15-25°C, with future capacity for storage at temperatures as low as -20°C.

Benefiel said the decision to locate the facility in Balerna was a strategic one because of its connection to local rail and highway networks. It is located about three hours south of Singota’s facility in Basil, Switzerland, which opened in 2019. The company also has a location in Rovello Porro, Italy.

“We’ve found the European market to be very attractive to folks who want to onshore perhaps from other regions of the world,” Benefiel said. “We’ve been cultivating our brand awareness in Europe specifically because we want to make sure that any European medicines have that access and play into the American market. We think that makes American health care more affordable and accessible. But also we want our American clients to be able to access that market in Europe.”

Founded in 2005, Singota Solutions provides pharmaceutical development, manufacturing and storage services for a variety of clients. Benefiel said the company, formerly known as BioConvergence, acts as a one-stop shop for early-stage injectable medicines.

“We do a lot in our lab with development formulation, with moving from a drug substance to a drug product, with helping figure out how to make a great, new, innovative medicine at scale,” she said. “We have a lot of great laboratory equipment, so we can help people solve previously impossible challenges, and then we can help you scale up to that first manufacturing batch.”

Looking ahead, Benefiel said the growth outlook for Singota, both in the U.S. and Europe, is limitless. Because the company is privately held, she said they can grow and expand in response to the needs of their clients.

“They may start with us just storing a couple of bottles of very expensive research grade material,” she said. “As they proceed towards clinical trial phase one, they may expand. They may need some development, formulation, process development, analytical method development help. So they can grow with us, and they can expand with us, and we can expand, in turn, to meet what they need us to do.”

Singota Solutions employs more than 100 people at its Bloomington facility and a total of 63 people at its Basil and Rovello Porro locations.